SUNRISE, Fla., Jan. 12, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT) announced today that it plans to conduct clinical trials for its second-generation MyoCell SDF-1 myogenic cell composition for treating advanced heart failure. The company believes that it may be able to fund these trials to a large extent with grant funding, which will be non-dilutive to the company’s investors. Earlier this year, Bioheart approached the National Heart, Lung and Blood Institute of the National Institutes of Health to discuss the possibility of their Cardiovascular Cell Therapy Research Network Centers to participate in these new clinical trials.
